Who
Garry A. Nicholson
Director
Company insider
Files Form 4 as: Director, TScan Therapeutics; Director, Day One Biopharmaceuticals; Director, G1 Therapeutics; Director, NextCure; Director, Turning Point Therapeutics; Director, Five Prime Therapeutics; Director, Tesaro.
In numbers
- Trades disclosed
- 75
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 1 Jun 2015
- Last trade
- 20 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 22 May 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —33,900 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —37,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,335 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —33,900 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —37,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,335 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —33,900 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —33,900 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —37,500 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,335 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —32,335 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.